Market Herald logo

Subscribe

Be the first with the news that moves the market
  • MGC Pharmaceuticals (MXC) has reported successful results from an ongoing research program aiming to develop a treatment for glioblastoma
  • The pre-clinical research program is testing novel cannabinoid formulations on the aggressive brain cancer which is so far therapeutically resistant
  • Results so far show that using a combination of cannabigerol (CBG) and cannabidiol (CBD) causes a significant number of the cancerous cells to self-destruct
  • Furthermore, the tests found CBG to be effective in targeting glioblastoma stem cells which are highly resistant to chemotherapy
  • MGC gained 3.33 per cent by market close with shares worth 3.1 cents each

MGC Pharmaceuticals (MXC) has reported successful results from an ongoing research program aiming to develop a treatment for glioblastoma.

The pre-clinical research program is testing novel cannabinoid formulations on the aggressive, primary brain cancer which is so far therapeutically resistant.

Results show that a multi-compound cannabinoid formulation is more effective than single cannabinoid preparations.

The research has found that using a combination of cannabigerol (CBG) and cannabidiol (CBD) inhibits tumour cell viability and causes a significant number of the glioblastoma cells to self-destruct via a process known as apoptosis.

This combination was sufficiently effective at inducing apoptosis, without the need for tetrahydrocannabinol (THC) which has psychotropic effects.

Furthermore, the formulation with CBG is shown to be able to target glioblastoma stem cells. These cells are highly resistant to chemotherapy meaning that even after initial treatment they can multiply and lead to tumour reassurance.

These stem cells have also been shown to be resistant to THC and CBD. However, in an experiment whereby the cancer stem cells were exposed to CBG, more than a third were dead two days later.

MGC Pharma Co-founder and Managing Director Roby Zomer explained how these results will be followed up in the ongoing research program.

“Further research, using the in-vitro diagnostic platform on a glioblastoma patient’s tumour cells will focus on the most effective CBG and CBD combination doses and doses of cannabinoids to approach individualised, informed treatment of patients, avoiding unwanted effects of THC.”

The research program is being conducted in partnership with the National Institute of Biology and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia. 

MGC gained 3.33 per cent by market close with shares worth 3.1 cents each.

MXC by the numbers
More From The Market Herald
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) locks in OmniCAR cell manufacturing contract for clinical trials

Prescient Therapeutics (ASX:PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce its…
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.
The Market Herald Video

" Proteomics International (ASX:PIQ) to raise $8m for Promarker development

Proteomics International (ASX:PIQ) receives firm commitments to raise $8 million to advance marketing, sales and further…